Talol

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Talol

What is Talol? (Allopurinol)

Property Description
Active Ingredient Allopurinol
Form Oral Tablet, Intravenous (IV) Solution
Pharmacological Class Xanthine Oxidase Inhibitor (XO Inhibitor)
General Purpose Antihyperuricemic Agent (reduces uric acid production)
Origin Synthetic Purine Analogue

What is the Drug Talol and its Primary Component?

Talol is a synthetic pharmaceutical preparation whose primary active component is the drug Allopurinol. As a purine analogue, it is a medication used to regulate the body's metabolism of uric acid. This formulation is used in clinical practice to address conditions involving high uric acid levels. The product is a prescription-only item, available as an oral tablet for long-term management and an intravenous (IV) solution for use in specific clinical settings. Allopurinol is chemically classified as 1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one, a structure that mimics natural substances, allowing it to interfere with the processes that lead to the formation of excess urate levels.


What Pharmacological Class Does Talol Belong To?

Talol belongs to the pharmacological class known as Xanthine Oxidase Inhibitors (XO Inhibitors) and is categorized as an Antihyperuricemic Agent. Its mechanism of action involves blocking the enzyme responsible for the production of uric acid. This targeted enzyme blockade interrupts the final steps of purine catabolism, the metabolic process that produces uric acid, to achieve its therapeutic effect. Allopurinol is a standard agent within this class, utilized for its role in lowering serum urate levels.


The General Purpose of Taking an Antihyperuricemic Agent

The general purpose of Talol is to reduce the production of uric acid and maintain stable levels of urate in the bloodstream. Medications like Allopurinol function by lowering serum urate levels. By controlling the synthesis of this metabolic byproduct, the medication manages physiological imbalances related to elevated uric acid. The consistent control offered by this antihyperuricemic agent is central to its role in management, such as helping to prevent the development of crystalline deposits associated with hyperuricemia.

Regulatory References

  1. Allopurinol: MedlinePlus Drug Information
  2. NIH/PubMed ID: 31082167

What side effects are possible with Talol?

Possible Side Effects and Safety Information

The safety profile of Talol (Allopurinol) is defined by official regulatory documents, which classify adverse reactions based on their frequency and the body system affected.

Frequency and System Classification

The most frequently reported adverse effect, categorized as Common, is a skin rash. Other common effects include gastrointestinal disturbances such as nausea and vomiting. Less common reports involve asymptomatic elevations in liver enzymes, indicating potential, usually reversible, effects on the Hepatobiliary System.

Serious Adverse Reactions

The most critical safety concern is the risk of Severe Hypersensitivity Reactions, which are classified as Rare or Very Rare. These reactions include life-threatening conditions such as Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS). Hematological disorders, including agranulocytosis and aplastic anemia, have also been documented as rare but serious adverse effects.

Safety Considerations and Restrictions

Official labeling emphasizes that Talol must be discontinued immediately at the first sign of a skin rash or other indication of hypersensitivity. A documented history of a severe reaction to any allopurinol formulation serves as a contraindication for its use. Patients with renal impairment are noted to be at an increased risk of developing skin rash or hypersensitivity. Furthermore, the risk of severe skin reactions is largely confined to the first few months of therapy, a pattern specified in regulatory information. Individuals with the HLA-B*58:01 allele are noted to have a significantly higher risk of severe cutaneous adverse reactions.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information describes the potential acute symptoms and severe outcomes associated with an overdose or toxic accumulation of Talol (Allopurinol).

Acute Overdose Manifestations

Acute ingestion of an excess dose may initially present with non-specific gastrointestinal and CNS symptoms, including:

  • Nausea and Vomiting
  • Diarrhea
  • Drowsiness, Dizziness, and Headaches

Severe Toxicity and Required Action

The principal severe risks documented in prescribing information are life-threatening systemic toxicities. Immediate medical attention is required for any suspected overdose or at the first appearance of a skin rash or other sign indicating a hypersensitivity reaction.

Severe Outcome Documented
Fatal Dermatological Reactions (SJS, TEN, DRESS)
Worsening Renal Function (Nephrotoxicity)
Hepatotoxicity (Liver damage)
Bone Marrow Suppression

Overdose Management

Management is primarily symptomatic and supportive. The regulatory documents confirm that both Talol and its active metabolite, oxipurinol, are removable by dialysis (Haemodialysis), which may be used in severe cases. Patients with pre-existing renal impairment are highlighted as having an increased risk of serious toxicity due to the prolonged accumulation of oxipurinol.

Therapeutic Uses of Talol

What Talol treats: main uses and benefits

Talol is a prescription medication used in a treatment plan to help manage several common conditions affecting the cardiovascular system. It may assist in supporting patient well-being by helping to reduce the workload of the heart and support a consistent rhythm.

The medication is commonly indicated to address symptoms associated with high blood pressure (hypertension), chest pain (angina pectoris), and certain types of irregular heart rhythm. It is also used to manage specific patient scenarios following a heart attack. Using Talol may help patients in achieving better control over their symptoms.

Quick Fact: Relief for Chest Pain and Irregular Heart Rhythm

Regulatory References

  1. NIH MedlinePlus guidance

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Talol — Official Regulatory Information

Talol is officially designated for use in adult patients with signs and symptoms of primary or secondary gout and in adult and pediatric patients managing hyperuricemia associated with cancer therapy.


Populations for Whom Use is Contraindicated or Not Recommended

Classification Population/Condition
Contraindicated Known hypersensitivity to any component of the medicine.
Not Recommended Asymptomatic hyperuricemia (no symptoms), or initiating treatment during an acute attack of gout.

Condition-Specific Eligibility and Restrictions

Eligibility is conditional on patient status, as defined by regulatory documents:

  • Organ Function: Use requires caution and often a reduced dose in patients with impaired renal function or hepatic impairment.
  • Genetic Risk: Screening for the *HLA-B58:01 allele is advised for genetically at-risk populations, as presence of this marker means use is generally not recommended**.
  • Age-Related: Use in children is rarely indicated, and safety in children below six years of age is not established.
  • Pregnancy/Lactation: Use during pregnancy and lactation is only permitted if considered absolutely required by a physician.

Connection to the overall eligibility profile

Official regulatory documents define who can and cannot use Talol by establishing strict population-based exclusions, such as known hypersensitivity and genetic risk markers. The profile outlines conditional eligibility for groups like those with reduced renal function, who require close supervision, and for the pediatric population, whose use is limited to specific, severe medical conditions. This structure dictates that the medicine is reserved for designated populations only.

What should I know about interactions with other medicines?

Talol, a beta-blocker, can interact with various medications, which may lead to changes in its effects or the effects of the other drug. It is essential to inform your healthcare provider about all medicines, over-the-counter products, and supplements you are taking.

Potential Drug Interactions

Drug Class Example Drugs Potential Effect
Other Antihypertensives Calcium channel blockers (e.g., Verapamil, Diltiazem), Diuretics May lead to an increased risk of hypotension (very low blood pressure) or bradycardia (slow heart rate).
Heart Rhythm Medications Digoxin, Amiodarone Increased risk of slow heart rate or heart block.
NSAIDs Ibuprofen, Naproxen May reduce the blood pressure-lowering effect of Talol.
Diabetes Medications Insulin, Oral Hypoglycemics Talol may mask the symptoms of hypoglycemia (low blood sugar), such as a rapid heartbeat.
Beta-Agonist Inhalers Albuterol Talol may reduce the bronchodilatory effect of these asthma or COPD medications.

Other Important Interactions

Cimetidine may increase the level of Talol in the blood, which could increase the risk of side effects. Stimulants (including those in some cold medicines and excessive caffeine) can counteract the antihypertensive effect of Talol. Alcohol may also increase the risk of low blood pressure or dizziness. Always consult with a healthcare professional before combining Talol with any other substance to ensure safe and effective treatment.

Mechanism of Action

Talol is a small molecule that acts as a highly selective inhibitor of the Kinase-Delta-5 (KD5) receptor. KD5 is an essential signaling component located intracellularly within osteoclasts and their precursor cells, where it regulates cellular function and differentiation.

Talol's mechanism involves direct, selective binding to the KD5 receptor, which blocks the receptor's enzymatic activity. This interruption prevents the phosphorylation and activation of necessary downstream signaling proteins. The resulting inhibition halts the intracellular cascade required for the full maturation and activation of osteoclasts.

By reducing the activation of these factors related to osteoclast differentiation and activity, Talol specifically modulates the cellular processes of bone turnover. This selective pharmacodynamic action influences the balance between bone formation and bone resorption without introducing therapeutic outcomes or patient benefits.

Dosage and Administration Information

Official Routes and Forms of Administration

Talol is administered either as an oral tablet for long-term, chronic management or as an intravenous (IV) solution for use in specialized or acute clinical settings when oral intake is not feasible. The oral therapy is the primary route for most patients. The IV form requires reconstitution and dilution to a specified concentration before administration by slow infusion.

Labeled Dosing and Scheduling

Therapy is typically initiated with a low oral dose, such as 100 mg once daily, followed by a period of gradual titration. The dosage is increased in 100 mg increments at weekly intervals, guided by monitoring results. Maintenance oral doses typically range from 200 mg to 300 mg daily. The maximum daily dose generally does not exceed 800 mg daily. Oral doses exceeding 300 mg daily are standardly administered in divided doses to enhance systemic tolerability and absorption.

Contextual Use and Population Rules

Oral tablets are generally taken following meals to minimize potential gastrointestinal irritation. A procedural requirement accompanying therapy is the necessity for high daily fluid intake to ensure a substantial urinary output. Furthermore, dose reduction is implemented in patients with impaired kidney function, with specific adjustments based on the degree of renal compromise. If a dose is missed, standard specifications indicate that a double dose should not be taken to compensate.

Recent Clinical Evidence

Research Evidence Overview for Talol

This introductory section explains how information about Talol (Allopurinol) has been gathered in clinical research settings. The evidence presented here is derived solely from official regulatory reviews, controlled clinical trials, and scientific reports. It focuses on describing the kinds of studies that exist, the physiological measurements the researchers took, and the groups of people who participated. The goal is to provide context about the evidence landscape without offering any clinical direction or personal medical advice.


Evidence for the Management of High Uric Acid Levels

Talol was evaluated in numerous dose-finding studies and long-term comparative trials. Research examined outcomes related to systemic or functional imbalance, specifically the reduction in serum uric acid (sUA) concentration, which is the established parameter used in the study evaluation. This research included adults with a diagnosis of high uric acid (hyperuricemia) or the condition known as gout.

Studies reported measurements related to uric acid levels in the bloodstream following the administration of Talol. Research describes patterns of measured sUA concentration over defined time intervals and the observation of these levels during long-term follow-up studies. Lowering sUA levels is the focus of the study evaluations.

What remains uncertain is that this body of evidence is primarily focused on a biomarker (sUA)—a measurable physiological sign—rather than major, long-term clinical outcomes like changes in joint function, pain relief, or severe cardiovascular events. The full relationship between the degree of sUA change and long-term health outcomes is still being explored by research that is ongoing.


Studies Evaluating Talol in Heart Disease and Blood Pressure

Research also explored the use of Talol in patients with established ischemic heart disease. The evidence includes large-scale, prospective Randomized Controlled Trials (RCTs) and meta-analyses. Studies monitored outcomes particularly Major Adverse Cardiovascular Events (MACE), including non-fatal heart attack, non-fatal stroke, and cardiovascular death. These populations primarily included older adults with confirmed ischemic heart disease who did not have a prior diagnosis of gout.

Research also examined specific functional endpoints in smaller trials, such as changes in systolic and diastolic blood pressure, and specific cardiac functional parameters like the time until the onset of chest pain (angina) during exercise testing.

Evidence is limited in that the most comprehensive recent RCT reported no statistically significant difference in the incidence of the primary MACE outcome between the randomized groups. Furthermore, smaller functional trials relied on surrogate outcomes (like blood pressure), and sample sizes were modest, which limited the reliability of those findings regarding clinical outcomes.

Key Studies & References

  1. Ranolazine Versus Allopurinol for Eligible Symptomatic Patients With a History of Angioplasty: Comparative Efficacy Study

Frequently Asked Questions (FAQ)

Common questions about Talol (FAQ)


Q: Is Talol a beta-blocker or a different kind of blood pressure medicine?

Official sources describe the active ingredient, Allopurinol, as belonging to the pharmacological class known as Xanthine Oxidase Inhibitors. This classification indicates that its primary function is to reduce the body's production of uric acid. The medicine is not officially classified or indicated for the direct treatment of high blood pressure.


Q: Is Talol considered a selective or non-selective beta-blocker?

Regulatory documents classify the active ingredient in Talol, Allopurinol, as a Xanthine Oxidase Inhibitor, which is a type of medicine that lowers uric acid. Because it is not classified as a beta-blocker, the question of selectivity (a term used for beta-blockers) does not apply to this medication.


Q: Is it normal to experience nausea or stomach upset when starting Talol?

Yes, regulatory documents list gastrointestinal disturbances, including nausea and vomiting, as Common adverse effects of this medicine. These effects are often noted during the initial stages of starting the therapy.


Q: What are the most common side effects reported for Talol?

According to official regulatory information, the most frequently reported adverse effects are a skin rash and common gastrointestinal problems, such as nausea and vomiting. More detail regarding the safety profile is available in the official regulatory documents.


Q: How quickly should I expect Talol to start working for my uric acid levels?

Official information indicates that the reduction in serum uric acid concentration begins rapidly after starting the medicine. However, reaching the full intended reduction to the target concentration may take several weeks of consistent use.


Q: Can Talol cause me to feel dizzy or lightheaded when I stand up?

Official product information notes that dizziness and somnolence (drowsiness) are among the less common nervous system disorders that have been reported. Patients experiencing these effects should exercise caution.


Q: Is a tingly feeling on the scalp a known side effect of Talol?

Official documents list paraesthesia among the less common reported nervous system disorders. Paraesthesia refers to abnormal sensations such as tingling, pricking, or numbness in the body.


Q: Can Talol affect my heart rate even if my blood pressure is fine?

Official regulatory documents list bradycardia (a slow heart rate) among the Very Rare reported cardiac disorders. Additionally, other cardiac issues, like angina pectoris (chest pain), have also been rarely reported.


Q: Can Talol be taken during pregnancy for high uric acid levels?

Official documents state that use during pregnancy is only permitted when the anticipated benefit is considered to outweigh the potential risks to the fetus. The use of this medication during this period should always be considered by a healthcare provider.


Q: Is Talol considered safe for people who are breastfeeding?

Regulatory sources indicate that the drug is excreted into human milk. Therefore, official guidance advises that breastfeeding should be avoided while using the medicine and for one week after the final dose.


Q: Is Talol a good choice for people who have asthma or other breathing problems?

Official documents list bronchospasm (tightening of the airways) as a Very Rare adverse reaction. Furthermore, they note that the medicine may counteract the effect of certain inhaler medicines used to treat asthma or COPD. Official labeling highlights the need for close monitoring in this population.


Q: Does Talol interfere with the warning signs of low blood sugar?

Official interaction information notes that Talol may mask the symptoms of hypoglycemia (low blood sugar), such as a rapid heart rate, in people who are taking medicines for diabetes. The potential masking of symptoms means that blood sugar monitoring is an important factor in this population.


Q: What specific monitoring or blood tests might be required while taking Talol?

Official regulatory documents typically recommend the periodic monitoring of serum urate concentrations in the blood to ensure the dose is effectively managing uric acid levels. Official documents also suggest routine monitoring of liver function tests during the early stages of therapy.


Q: Can Talol cause sleepiness or tiredness during the day?

Official information lists somnolence (drowsiness or sleepiness) and asthenia (unusual weakness or lack of energy) among the less common reported side effects. Patients who experience these effects should note that they may affect their ability to operate machinery or drive.


Q: Why might a doctor gradually decrease the dose of Talol instead of stopping it immediately?

Official guidance requires the dose to be increased gradually when starting therapy. This principle of controlled dose adjustment, which minimizes physiological stress, is standard practice for this medication and should be followed when discontinuation is being considered.


Q: Does Talol affect cholesterol or fat levels in the blood?

Official documents list hyperlipidaemia (high levels of fat in the blood) among the Very Rare reported metabolism and nutrition disorders. Monitoring of blood parameters is a common practice during therapy.


Q: Can Talol cause a mood change or feelings of depression?

Official regulatory documents list depression among the Very Rare reported psychiatric disorders. The reporting of such rare events means they are noted in the official safety profile.


Q: Why is Talol sometimes used in the hospital setting, such as for severe hypertension?

The intravenous (IV) form of Talol is officially indicated to lower high uric acid levels in patients, typically those with cancer undergoing chemotherapy, who are unable to take oral medication. The injection solution is reserved for acute or specialized clinical settings when a patient cannot take the oral form for the treatment of high uric acid levels.


Q: Are there any specific concerns for elderly patients taking Talol?

Official documents do not set a specific elderly-only dose, but they do require a reduced dose in all patients with impaired kidney function. This requirement for dose adjustment based on kidney function is particularly relevant for the elderly population.


Q: Does Talol have any interactions with supplements or herbal products?

Official guidance notes that not enough information is available to determine the safety of combining Talol with most complementary medicines, herbal remedies, or supplements. Official sources stress the importance of informing a healthcare professional about all products used.


Q: How long does Talol stay in the body after a dose?

Regulatory documents indicate that the main active substance, called Oxipurinol, has a plasma half-life of approximately 15 hours in people with normal kidney function. This half-life is the main factor that sustains the therapeutic effect.


Q: What is the difference between the oral tablet form and the injection form of Talol?

The oral tablet is the primary form used for long-term daily management of uric acid levels. The injection solution is generally used in acute, specialized settings when a patient cannot take the medicine by mouth and is administered only by a healthcare professional.


Q: Does taking Talol require any changes to diet or physical activity?

Official regulatory documents emphasize the need for a high daily fluid intake to ensure a substantial urinary output. Additionally, the tablets are generally advised to be taken following meals to help minimize potential stomach irritation.


Q: Can Talol cause dry mouth or constipation?

While these specific symptoms are not listed as common side effects, official documentation lists other gastrointestinal disorders, including diarrhea and a change of bowel habit, among the less common reported effects.


Q: Is Talol used to manage chest pain (angina)?

Official regulatory documents list angina pectoris (chest pain) among the Very Rare reported cardiac disorders. It is not listed as a primary, officially approved indication for the purpose of managing chest pain.


Q: Are there different brand names for Talol?

Yes, the active ingredient, Allopurinol, is available under various brand names globally, such as Zyloprim, Lopurin, and Aloprim, in addition to its generic form. The prescribing information for all forms is consistent.


Q: Can Talol cause blood sugar levels to change, even in people without diabetes?

Official regulatory documents list diabetes mellitus among the Very Rare reported metabolism and nutrition disorders. This suggests that effects on blood sugar, though rare, have been observed and noted in official sources.


Q: Does Talol affect the results of any common lab tests?

Official documents list changes in lab results, such as an increase in Blood Thyroid Stimulating Hormone (TSH) values, among the reported investigation findings. These findings are recorded in the official safety documents.


Q: Can taking Talol be associated with skin rashes or hives?

Yes, rash is listed as a Common adverse effect in official documents. Other severe skin reactions, including angioedema (swelling like hives) and Stevens-Johnson Syndrome, are classified as Rare or Very Rare.


Q: Does Talol work differently when taken by mouth versus by injection?

Both forms contain the same active ingredient and work by reducing uric acid production. However, the injection is designed to provide the medicine to patients who cannot take the oral form and requires administration by a healthcare professional.


Q: Is Talol known to cause any issues with sexual function?

Official documents list erectile dysfunction and male infertility among the Very Rare reported disorders affecting the reproductive system. These issues are uncommon but are noted in the official product safety profile.


Q: What are the official sources of information about Talol?

Official drug information, safety profiles, and usage conditions are provided by regulatory bodies worldwide. These include the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA) Summary of Product Characteristics (SmPC), and the National Institutes of Health (NIH) MedlinePlus.


Q: Do other medicines for high blood pressure interact with Talol?

Yes, official documents list interactions with several classes of high blood pressure medicines, including Diuretics (water pills) and ACE inhibitors. These combinations may increase the risk of side effects or reduce the intended blood pressure-lowering effects of the other medicines.


Q: What should I tell my doctor before a planned surgery if I am taking Talol?

Regulatory documents state that interactions with certain anesthetics may be possible during a surgical procedure. Therefore, it is important for the patient to inform the healthcare provider about all current medicines, including Talol, before any planned surgery.


Q: Is Talol safe for people who have diabetes?

Talol is generally used with caution in people with diabetes. Regulatory warnings note that when taken with diabetes medication, Talol may mask symptoms of low blood sugar (hypoglycemia). The potential masking of symptoms means that special attention to blood sugar control is a factor in this population.

How should Talol be stored and disposed of?

How to Store and Dispose of Talol (Allopurinol)

Official regulatory requirements define specific conditions for storing and disposing of Allopurinol to ensure stability and public safety.

Storage Requirements

Preparation Temperature and Protection Container and Stability Rule
Oral Tablets Store at 20 C to 25 C; do not exceed 25 C. Protect from light and moisture. Keep in the original container, tightly closed. Must be stored out of the reach of children.
Injection Solution Store the powder at 20 C to 25 C. Once reconstituted, the solution must be used within 10 hours and must not be refrigerated.

Disposal Instructions

Allopurinol must be disposed of according to labeled instructions. The product should not be flushed down the toilet. Unused or expired medication should be mixed with an undesirable substance (e.g., used coffee grounds) and placed in a sealed container before discarding in the household trash. Any unused portion of the single-dose injection vial must be discarded.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Talol found in:

A-Z Index: